ProQR Therapeutics has entered into a research collaboration with Galapagos to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets selected by Galapagos. ProQR is developing its RNA platform technology in areas of ophthalmology, cystic fibrosis and dystrophic epidermolysis bullosa. Through a collaboration with Amylon Therapeutics, the platform is also being developed for CNS indications including HCHWA-D. Recently, validation and expansion of the platform included ...